Wall Street analyst estimates for MBX Biosciences, Inc. Common Stock (MBX): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism.
Consensus price target
$100.00 (+91% vs price $52.48)
between $84.00 and $150.00 · 4 targets published in the last quarter
Closing price, Nov 4
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | -$3.07 | 7 | ||
| 2027E | -$3.98 | 7 | ||
| 2028E | $35.3M | $35.3M – $35.3M | -$4.41 | 7 |
Figures in USD · consensus as of November 1, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 7 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 7 |
| Avg rating (−2 sell to +2 buy) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.83 | ||
| 2026-08-06 | $-0.78 | $-0.63 | -23.3% |
| 2026-05-07 | $-0.51 | $-0.62 | +17.7% |
| 2026-03-12 | $-0.49 | $-0.64 | +23.4% |
| 2025-11-06 | $-0.63 | $-0.73 | +13.7% |
| 2025-08-07 | $-0.58 | $-0.77 | +24.7% |
| 2025-05-12 | $-0.71 | $-0.81 | +12.3% |
| 2025-03-17 | $-0.47 | $-0.59 | +20.3% |
Valuation Ratios
| Price / Book | 6.11 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | $248,000 |
| Gross Profit | 0 | 0 | 0 | -$248,000 |
| Research & Development | $21.4M | $28.5M | $57.4M | $79.2M |
| Selling, General & Admin | $3.8M | $6.8M | $10.8M | $18.9M |
| Operating Expenses | $25.2M | $35.3M | $68.2M | $98.1M |
| Operating Income | -$25.2M | -$35.3M | -$68.2M | -$98.1M |
| EBITDA | -$25.7M | -$32.4M | -$61.7M | -$86.7M |
| Interest Expense | $374,000 | 0 | 0 | 0 |
| Pre-tax Income | -$26.1M | -$32.6M | -$61.9M | -$87.0M |
| Income Tax | 0 | 0 | 0 | 0 |
| Net Income | -$26.1M | -$32.6M | -$61.9M | -$87.0M |
| EPS | -$0.82 | -$1.02 | -$1.85 | -$2.38 |
| EPS (Diluted) | -$0.82 | -$1.02 | -$1.85 | -$2.38 |
| Shares Outstanding (Diluted) | 31.9 M | 31.9 M | 33.4 M | 36.5 M |
Price
| Price | $52.48 (closing price, November 4, 2026) |
| Market Cap | $2.5B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ASND · RYTM · VKTX · VRTX · 0QZU.L · MRNA · REGN · 0R2M.L
Explore sector: Healthcare · Biotechnology
More sections of MBX: Overview · Financials · Valuation · Technical · Ownership
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks